Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial
James Chih‐Hsin Yang(National Taiwan University), Jin‐Yuan Shih(National Taiwan University), Wu‐Chou Su(National Cheng Kung University), Te‐Chun Hsia(China Medical University), Chun-Ming Tsai(Taipei Veterans General Hospital), Sai‐Hong Ignatius Ou(University of California, Irvine), Chong‐Jen Yu(National Taiwan University), Gee‐Chen Chang(National Yang Ming University Hospital), Ching-Liang Ho(National Defense Medical Center), Lecia V. Sequist(Harvard University Press), Arkadiusz Z. Dudek(University of Minnesota), Mehdi Shahidi(Boehringer Ingelheim (Egypt)), Xiuyu Julie Cong(Boehringer Ingelheim (United States)), Robert M. Lorence(Boehringer Ingelheim (United States)), Pan‐Chyr Yang(National Taiwan University), Vincent A. Miller(Memorial Sloan Kettering Cancer Center)
Cited by 404
Abstract
Related Papers
No related papers found
Powered by citation graph analysis